These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 18784934

  • 1. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab.
    Reich K, Griffiths CE.
    Arch Dermatol Res; 2008 Nov; 300(10):537-44. PubMed ID: 18784934
    [Abstract] [Full Text] [Related]

  • 2. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [Abstract] [Full Text] [Related]

  • 3. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
    Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter A.
    Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
    [Abstract] [Full Text] [Related]

  • 4. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE.
    Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
    [Abstract] [Full Text] [Related]

  • 5. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.
    Dermatology; 2008 Jun; 216(3):260-70. PubMed ID: 18187944
    [Abstract] [Full Text] [Related]

  • 6. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
    Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas AD.
    Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
    [Abstract] [Full Text] [Related]

  • 7. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [Abstract] [Full Text] [Related]

  • 8. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab.
    Torii H, Sato N, Yoshinari T, Nakagawa H, Japanese Infliximab Study Investigators.
    J Dermatol; 2012 Mar; 39(3):253-9. PubMed ID: 22211581
    [Abstract] [Full Text] [Related]

  • 9. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG.
    Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
    [Abstract] [Full Text] [Related]

  • 10. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
    Katugampola RP, Lewis VJ, Finlay AY.
    Br J Dermatol; 2007 May; 156(5):945-50. PubMed ID: 17388922
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
    Puig L.
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
    [Abstract] [Full Text] [Related]

  • 12. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI, PEARL investigators.
    J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
    [Abstract] [Full Text] [Related]

  • 13. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany.
    Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K.
    Dermatology; 2008 Aug; 216(4):366-72. PubMed ID: 18319601
    [Abstract] [Full Text] [Related]

  • 14. The effect of treatment on quality of life in psoriasis patients.
    Prins M, Krabbe PF, Swinkels QO, de Boo T, van de Kerkhof PC, van der Valk PG.
    Acta Derm Venereol; 2005 Aug; 85(4):304-10. PubMed ID: 16191850
    [Abstract] [Full Text] [Related]

  • 15. Approach to managing patients with nail psoriasis.
    Reich K.
    J Eur Acad Dermatol Venereol; 2009 Sep; 23 Suppl 1():15-21. PubMed ID: 19686381
    [Abstract] [Full Text] [Related]

  • 16. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.
    Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG.
    J Am Acad Dermatol; 2004 Jun; 50(6):859-66. PubMed ID: 15153885
    [Abstract] [Full Text] [Related]

  • 17. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
    Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CE.
    Eur J Dermatol; 2007 Jun; 17(5):381-6. PubMed ID: 17673380
    [Abstract] [Full Text] [Related]

  • 18. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
    Jacobson CC, Kimball AB.
    Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545
    [Abstract] [Full Text] [Related]

  • 19. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting.
    de Korte J, van der Valk PG, Sprangers MA, Damstra RJ, Kunkeler AC, Lijnen RL, Oranje AP, de Rie MA, de Waard-van der Spek FB, Hol CW, van de Kerkhof PC.
    Br J Dermatol; 2008 Feb; 158(2):375-81. PubMed ID: 18067483
    [Abstract] [Full Text] [Related]

  • 20. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
    Norlin JM, Nilsson K, Persson U, Schmitt-Egenolf M.
    Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.